Munich, Germany, March 8th 2022: Nanion is pleased to announce that a SyncroPatch 384 instrument has been installed at the Food and Drug Administration (FDA) at their Silver Spring site in Maryland. The SyncroPatch 384 will be used for high throughput automated patch clamp experiments for cardiac safety experiments.
MUNICH, GERMANY, July 7th 2021: Nanion is pleased to announce the launch of the SyncroPatch 384.
Munich, Germany, May 1st 2021:
Assessing preclinical cardiac contractility without animal use, but with human iPSC-derived cardiomyocytes is not only attractive for people in the cardiac community!
Parliamentary State Secretary Thomas Rachel (representing the Federal Ministry of Education & Research) stopped by InnoVitro headquarters in Juelich to award them with a 200k grant for the support of the new project SMOOTH: “Semi–synthetic Muscle Organoids based On Tissue Hybrids”
Munich, Germany, April 17th 2020: Nanion Technologies GmbH, a leading provider of automated patch clamp and cell monitoring systems, announces the partnership with NEXEL Co., Ltd., specialists in the manufacturing of hiPSC-derived cells. Under the partnership NEXEL will provide demonstration infrastructure in South Korea for Nanion´s CardioExcyte 96 and FLEXcyte 96 cell monitoring systems, while Nanion will provide scientific proficiency in experimental design and assay development.
